Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Benmelstobart - Apollomics/Chia Tai Tianqing Pharmaceutical Group

X
Drug Profile

Benmelstobart - Apollomics/Chia Tai Tianqing Pharmaceutical Group

Alternative Names: Anti-PD-L1 monoclonal antibody - Apollomics/Chia Tai Tianqing Pharmaceutical Group; APL 502; CBT-502; PD-L1 antibody - Apollomics/Chia Tai Tianqing Pharmaceutical Group​; TQ-B2450

Latest Information Update: 17 May 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Apollomics; Crown Bioscience
  • Developer Apollomics; Chia Tai Tianqing Pharmaceutical Group
  • Class Antineoplastics; Antivirals; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Programmed cell death-1 ligand-1 inhibitors; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Small cell lung cancer
  • Preregistration Endometrial cancer
  • Phase III Biliary cancer; Non-small cell lung cancer; Ovarian cancer; Renal cancer; Squamous cell cancer
  • Phase II/III Adenocarcinoma; Gastric cancer
  • Phase II Diffuse large B cell lymphoma; Gynaecological cancer; Hepatitis B; Hodgkin's disease; Liver cancer; Nasopharyngeal cancer; Uterine cancer
  • Phase I/II Acral lentiginous melanoma; Cholangiocarcinoma
  • Phase I Solid tumours
  • No development reported Triple negative breast cancer

Most Recent Events

  • 11 May 2024 Launched for Small cell lung cancer (Combination therapy, First-line therapy, Late-stage disease) in China (IV) - First Global Launch
  • 09 May 2024 Registered for Small cell lung cancer (Combination therapy, First-line therapy, Late-stage disease) in China (IV) - First Global Approval
  • 09 May 2024 Adverse events and efficacy data from a phase III trial in Small cell lung cancer released by Sino Biopharmaceuticals
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top